Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
Primary Purpose
HIV Infections
Status
Completed
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Amprenavir (drug)
ABT-378/r (drug)
Ritonavir (drug)
Sponsored by

About this trial
This is an interventional treatment trial for HIV Infections focused on measuring HIV infections, Salvage therapy, Amprenavir, Lopinavir, Ritonavir
Eligibility Criteria
Inclusion Criteria: Documented HIV infection CD4 cell count below 300/mm3 Plasma HIV RNA over 30,000 copies/ml Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir) Written informed consent Exclusion Criteria: Biological abnormalities Pregnancy Alcool abuse History of pancreatitis, hepatic failure Acute HIV related infection Chemotherapy
Sites / Locations
Outcomes
Primary Outcome Measures
Mean change of VIH RNA between week 0 and week 26
Secondary Outcome Measures
Disease progression
CD4 cell count
Safety
Pharmacokinetics
Genotypic resistance
Full Information
NCT ID
NCT00196625
First Posted
September 12, 2005
Last Updated
September 12, 2005
Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
1. Study Identification
Unique Protocol Identification Number
NCT00196625
Brief Title
Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
Official Title
Study on Safety and Efficacy of Salvage Therapy With Amprenavir, Lopinavir and Ritonavir 200 Mg/d or 400 Mg/d in HIV-Infected Patients in Virological Failure.ANRS 104 PUZZLE 1
Study Type
Interventional
2. Study Status
Record Verification Date
September 2005
Overall Recruitment Status
Completed
Study Start Date
November 2000 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
February 2002 (undefined)
3. Sponsor/Collaborators
Name of the Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
4. Oversight
5. Study Description
Brief Summary
HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors, over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed.
Detailed Description
HIV infected patients are treated with highly active antiretroviral therapy (HAART). Side effects and the great number of pills reduces adherence to the treatment, and induces therapeutic failure. In order to maintain efficacy of HAART, new combination is evaluated. The aim of the study is to compare the antiviral efficacy of this salvage therapy combining lopinavir and amprenavir with 200 mg/d or 400 mg/d ritonavir, together with nucleoside reverse transcriptase inhibitors (NRTI), over a 26-week period in HIV-infected patients in whom multiple antiretroviral regimens had failed. 100 patients with CD4 cell count below 300/mm3 and plasma HIV RNA over 30,000 copies/ml are to be included in four groups: amprenavir, lopinavir, NRTI, with ritonavir 200 mg.d or not (patients previously treated by additional ritonavir 200 or 400 mg/d).
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infections
Keywords
HIV infections, Salvage therapy, Amprenavir, Lopinavir, Ritonavir
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
100 (false)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Amprenavir (drug)
Intervention Type
Drug
Intervention Name(s)
ABT-378/r (drug)
Intervention Type
Drug
Intervention Name(s)
Ritonavir (drug)
Primary Outcome Measure Information:
Title
Mean change of VIH RNA between week 0 and week 26
Secondary Outcome Measure Information:
Title
Disease progression
Title
CD4 cell count
Title
Safety
Title
Pharmacokinetics
Title
Genotypic resistance
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Documented HIV infection
CD4 cell count below 300/mm3
Plasma HIV RNA over 30,000 copies/ml
Previously treated with 2 protease inhibitors and 1 non nucleoside analogue (except amprenavir, lopinavir)
Written informed consent
Exclusion Criteria:
Biological abnormalities
Pregnancy
Alcool abuse
History of pancreatitis, hepatic failure
Acute HIV related infection
Chemotherapy
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Gilles Raguin, MD
Organizational Affiliation
Service des Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, Paris, France
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Genevieve Chene, MD, PhD
Organizational Affiliation
INSERM U593, Bordeaux, France
Official's Role
Study Director
12. IPD Sharing Statement
Citations:
PubMed Identifier
15456093
Citation
Raguin G, Chene G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM; Puzzle 1 Study Group. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure. Antivir Ther. 2004 Aug;9(4):615-25.
Results Reference
result
PubMed Identifier
15060509
Citation
Taburet AM, Raguin G, Le Tiec C, Droz C, Barrail A, Vincent I, Morand-Joubert L, Chene G, Clavel F, Girard PM. Interactions between amprenavir and the lopinavir-ritonavir combination in heavily pretreated patients infected with human immunodeficiency virus. Clin Pharmacol Ther. 2004 Apr;75(4):310-23. doi: 10.1016/j.clpt.2003.12.013.
Results Reference
result
Learn more about this trial
Salvage Therapy With Amprenavir, Lopinavir and Ritonavir in HIV-Infected Patients in Virological Failure.
We'll reach out to this number within 24 hrs